About VolitionRX Ltd (NYSEMKT:VNRX)
VolitionRx Limited is a clinical-stage life sciences company. The Company is focused on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The Company has developed approximately 30 blood-based assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease. The Company's Nucleosomics biomarker platform is a technology that is used for a range of cancers. The Company is developing Nucleosomics tests for various cancers, including colorectal, pancreatic, lung and aggressive prostate. The Company's NuQ blood assays fall into over five types, which include NuQ-X, NuQ-V, NuQ-M, NuQ-A and NuQ-T. It has developed approximately two blood assays in the NuQ-X family to detect the presence of cancer by detecting nucleosomes containing specific nucleotides.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Diagnostic & Testing Substances
- Sub-Industry: N/A
- Symbol: NYSEMKT:VNRX
- CUSIP: N/A
- Web: www.volitionrx.com/
- Market Cap: $59.67 million
- Outstanding Shares: 26,518,000
- 50 Day Moving Avg: $2.66
- 200 Day Moving Avg: $3.18
- 52 Week Range: $2.25 - $5.45
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.95
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $0.63 per share
- Price / Book: 3.57
- EBITDA: ($13,230,000.00)
- Return on Equity: -79.20%
- Return on Assets: -63.86%
- Average Volume: 37,923 shs.
- Beta: -1.58
- Short Ratio: 3.43
Frequently Asked Questions for VolitionRX Ltd (NYSEMKT:VNRX)
What is VolitionRX Ltd's stock symbol?
VolitionRX Ltd trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "VNRX."
How were VolitionRX Ltd's earnings last quarter?
VolitionRX Ltd (NYSEMKT:VNRX) released its earnings results on Thursday, May, 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.01. View VolitionRX Ltd's Earnings History.
When will VolitionRX Ltd make its next earnings announcement?
Where is VolitionRX Ltd's stock going? Where will VolitionRX Ltd's stock price be in 2017?
1 analysts have issued 1-year target prices for VolitionRX Ltd's shares. Their forecasts range from $10.00 to $10.00. On average, they expect VolitionRX Ltd's stock price to reach $10.00 in the next year. View Analyst Ratings for VolitionRX Ltd.
Who are some of VolitionRX Ltd's key competitors?
Some companies that are related to VolitionRX Ltd include Synthetic Biologics (SYN), DURECT (DRRX), Matinas BioPharma Holdings (MTNB), Summit Therapeutics PLC (SUMM), Nobilis Health Corp (HLTH), Motif Bio PLC (MTFB), Immunodiagnostic Systems Holdings PLC (IDH), Galectin Therapeutics (GALT), Ergomed PLC (ERGO), ArQule (ARQL), Five Star Senior Living (FVE), Ampio Pharmaceuticals (AMPE), Presbia PLC (LENS), Diurnal Group PLC (DNL), Tissue Regenix Group PLC (TRX), Vernalis plc (VER), Navidea Biopharmaceuticals (NAVB) and NovaBay Pharmaceuticals (NBY).
Who are VolitionRX Ltd's key executives?
VolitionRX Ltd's management team includes the folowing people:
- Martin Charles Faulkes, Executive Chairman of the Board
- Cameron John Reynolds, President, Chief Executive Officer, Director
- David Vanston, Chief Financial Officer, Treasurer
- Louise Dayas, Chief Marketing and Communications Officer
- Jason Bradley Terrell, Chief Medical Officer and Head of US Operations
- Rodney Gerard Rootsaert, Secretary
- Alan Colman, Director
- Edward W. Futcher Ph.D., Independent Director
- Guy Archibald Innes, Independent Director
- Habib Skaff, Independent Director
How do I buy VolitionRX Ltd stock?
Shares of VolitionRX Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is VolitionRX Ltd's stock price today?
MarketBeat Community Rating for VolitionRX Ltd (NYSEMKT VNRX)MarketBeat's community ratings are surveys of what our community members think about VolitionRX Ltd and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of VolitionRX Ltd stock can currently be purchased for approximately $2.25.
Consensus Ratings for VolitionRX Ltd (NYSEMKT:VNRX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Buy Rating|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$10.00|Consensus Price Target History for VolitionRX Ltd (NYSEMKT:VNRX)
Analysts' Ratings History for VolitionRX Ltd (NYSEMKT:VNRX)
(Data available from 10/22/2015 forward)
|9/20/2017||HC Wainwright||Reiterated Rating||Buy||$10.00|
|9/7/2016||Rodman & Renshaw||Lower Price Target||Buy||$12.00 -> $10.00|
Earnings History for VolitionRX Ltd (NYSEMKT:VNRX)Earnings History by Quarter for VolitionRX Ltd (NYSEMKT VNRX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/9/2017|| || || || || || || || |
|11/6/2014||($0.09)||($0.13)||$0.13 million||$0.02 million||View||N/A|
Earnings Estimates for VolitionRX Ltd (NYSEMKT:VNRX)
Current Year EPS Consensus Estimate: $-0.55 EPS
Next Year EPS Consensus Estimate: $-0.57 EPS
Dividend History for VolitionRX Ltd (NYSEMKT:VNRX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for VolitionRX Ltd (NYSEMKT:VNRX)Insider Trades by Quarter for VolitionRX Ltd (NYSEMKT:VNRX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/19/2017||David Cecil Vanston||Insider||Buy||2,750||$2.84||$7,810.00|| |
|8/16/2017||Cameron John Reynolds||Insider||Buy||3,630||$2.77||$10,055.10|| |
|10/5/2016||David Matthew Kratochvil||CFO||Buy||10,000||$5.00||$50,000.00|| |
|5/20/2016||Cameron John Reynolds||CEO||Sell||3,390||$3.54||$12,000.60|| |
|5/15/2015||Cameron John Reynolds||CEO||Buy||1,500||$3.33||$4,995.00|| |
|2/11/2015||Guy Archibald Innes||Director||Buy||50,000||$3.75||$187,500.00|| |
|9/15/2014||Martin Charles Faulkes||Director||Buy||5,000||$2.16||$10,800.00|| |
|9/3/2014||Rodney Gerard Rootsaert||Insider||Sell||28,000||$1.80||$50,400.00|| |
Headline Trends for VolitionRX Ltd (NYSEMKT:VNRX)
Latest Headlines for VolitionRX Ltd (NYSEMKT:VNRX)
Loading headlines, please wait.
VolitionRX Ltd (VNRX) Chart for Sunday, October, 22, 2017